← Quidel overview

Quidel vs Blue Sail Medical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Quidel Corporation (QDEL)

Q3 2026
▼3▲1

QuidelOrtho slashes 2026 outlook on China and respiratory weakness

  • 2026 guidance slashed, shares plunge QuidelOrtho beat second-quarter estimates but cut full-year 2026 revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and earnings guidance to 65-90 cents from $1.80-$2.00. Shares fell about 25% as investors absorbed the much weaker outlook.

    The guidance cut is the single biggest new force pushing QDEL down this period.

  • China pricing rules and weak respiratory season China's draft in-vitro diagnostics pricing guidelines expanded to six provinces, causing distributors to cut inventories faster than expected; China revenue fell 18.7%. Management also now assumes a weaker-than-average respiratory season, removing a hoped-for rebound.

    These are the specific demand problems management blamed for the guidance cut.

  • Analyst fair value and targets cut Simply Wall St cut its fair value estimate to $12 from $20.50, citing much lower growth assumptions. Analyst targets now cluster between $12 and $18, with JPMorgan at $12 (Underweight) and Citi at $18 (Neutral), showing deep disagreement on the stock's path.

    It shows how professional valuations were reset lower after the guidance cut.

  • Possible point-of-care sale could cut debt QuidelOrtho is reportedly looking to sell its point-of-care division for about $1.5 billion, which would undo the 2022 merger and leave a steadier diagnostics business. One large holder sees the stock worth roughly $100 per share if the sale happens and debt falls.

    It is the main potential upside counterweight to the weak guidance.

August 2026
▼3▲1

QuidelOrtho slashes 2026 outlook on China and respiratory weakness

  • 2026 guidance slashed, shares plunge QuidelOrtho beat second-quarter estimates but cut full-year 2026 revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and earnings guidance to 65-90 cents from $1.80-$2.00. Shares fell about 25% as investors absorbed the much weaker outlook.

    The guidance cut is the single biggest new force pushing QDEL down this period.

  • China pricing rules and weak respiratory season China's draft in-vitro diagnostics pricing guidelines expanded to six provinces, causing distributors to cut inventories faster than expected; China revenue fell 18.7%. Management also now assumes a weaker-than-average respiratory season, removing a hoped-for rebound.

    These are the specific demand problems management blamed for the guidance cut.

  • Analyst fair value and targets cut Simply Wall St cut its fair value estimate to $12 from $20.50, citing much lower growth assumptions. Analyst targets now cluster between $12 and $18, with JPMorgan at $12 (Underweight) and Citi at $18 (Neutral), showing deep disagreement on the stock's path.

    It shows how professional valuations were reset lower after the guidance cut.

  • Possible point-of-care sale could cut debt QuidelOrtho is reportedly looking to sell its point-of-care division for about $1.5 billion, which would undo the 2022 merger and leave a steadier diagnostics business. One large holder sees the stock worth roughly $100 per share if the sale happens and debt falls.

    It is the main potential upside counterweight to the weak guidance.

Latest
▼3▲1

QuidelOrtho slashes 2026 outlook on China and respiratory weakness

  • 2026 guidance slashed, shares plunge QuidelOrtho beat second-quarter estimates but cut full-year 2026 revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, and earnings guidance to 65-90 cents from $1.80-$2.00. Shares fell about 25% as investors absorbed the much weaker outlook.

    The guidance cut is the single biggest new force pushing QDEL down this period.

  • China pricing rules and weak respiratory season China's draft in-vitro diagnostics pricing guidelines expanded to six provinces, causing distributors to cut inventories faster than expected; China revenue fell 18.7%. Management also now assumes a weaker-than-average respiratory season, removing a hoped-for rebound.

    These are the specific demand problems management blamed for the guidance cut.

  • Analyst fair value and targets cut Simply Wall St cut its fair value estimate to $12 from $20.50, citing much lower growth assumptions. Analyst targets now cluster between $12 and $18, with JPMorgan at $12 (Underweight) and Citi at $18 (Neutral), showing deep disagreement on the stock's path.

    It shows how professional valuations were reset lower after the guidance cut.

  • Possible point-of-care sale could cut debt QuidelOrtho is reportedly looking to sell its point-of-care division for about $1.5 billion, which would undo the 2022 merger and leave a steadier diagnostics business. One large holder sees the stock worth roughly $100 per share if the sale happens and debt falls.

    It is the main potential upside counterweight to the weak guidance.

Blue Sail Medical Co Ltd (002382.CS)

Q3 2026
▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

  • First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.

    The profit turnaround is the central new fact that answers why the stock is moving.

  • Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.

    It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.

  • Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.

    The completed divestment is a new capital event that improves cash and focus.

  • Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.

    It is the real counterweight explaining why profit is much lower than divisional results.

August 2026
▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

  • First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.

    The profit turnaround is the central new fact that answers why the stock is moving.

  • Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.

    It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.

  • Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.

    The completed divestment is a new capital event that improves cash and focus.

  • Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.

    It is the real counterweight explaining why profit is much lower than divisional results.

Latest
▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

  • First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.

    The profit turnaround is the central new fact that answers why the stock is moving.

  • Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.

    It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.

  • Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.

    The completed divestment is a new capital event that improves cash and focus.

  • Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.

    It is the real counterweight explaining why profit is much lower than divisional results.